Can a drug duo save insulin-making cells in type 1 diabetes?
NCT ID NCT05742243
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether combining two safe immune therapies—abatacept injections and nasal insulin—can help preserve the pancreas's ability to make insulin in people recently diagnosed with type 1 diabetes. The goal is to make blood sugar control easier and reduce the need for injected insulin. The trial involved 68 participants aged 6 to 21, who received treatment for 48 weeks and were followed for another 48 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Perth Children's Hospital
Nedlands, Western Australia, 6009, Australia
-
Queensland Children's Hospital
South Brisbane, Queensland, 4101, Australia
-
The Children's Hospital at Westmead
Westmead, New South Wales, 2145, Australia
-
The Royal Children's Hospital
Parkville, Victoria, 3052, Australia
-
The Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
Women's and Children's Hospital
North Adelaide, South Australia, 5006, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an app and cash rewards tame type 1 diabetes in young adults?
- Could a stress hormone be behind the hidden danger of low blood sugar?
- Smart insulin pump aims to end dangerous nighttime blood sugar swings
- Could diabetes be silently damaging your hearing?
- Can a peptide tame type 1 diabetes?
- Hidden liver risk in type 1 diabetes: a new study investigates